Anticoagulation in CVD: Clinical Implications of the COMPASS Study

Jun 17, 2020

Overview :   Anticoagulation In Patients With Ischaemic Heart Disease And Peripheral Arterial Disease: Clinical Implications Of COMPASS Study Atherosclerotic cardiovascular disease (CVD) comprises a large number of related pathologies, including ischaemic heart disease and peripheral arterial disease (PAD).1 This group of... more

New Advances in the Management of Refractory Angina Pectoris

Apr 10, 2020

Overview :   Refractory angina (RA) is defined as chronic angina-type chest pain (duration ≥ 3 months) associated with reversible ischaemia that persists despite optimal medical, interventional and surgical management.1 The clinical burden of RA is growing due to an ageing population... more

Women with Stable Angina Pectoris and No Obstructive Coronary Artery Disease: Closer to a Diagnosis

Nov 15, 2018

Overview :   Women have for many years been regarded as being at relatively low risk for the development of ischaemic heart disease (IHD).1,2 Recently this pattern has changed and cardiovascular disease (CVD) is now the leading cause of death for women in... more

Cardiovascular Risk Management Targeting Inflammation In Addition To Lipid-Lowering Therapy

Dec 13, 2017

Overview : Myocardial infarction is often caused by the rupture of unstable plaque in atherosclerosis with mild-to-moderate stenosis. Research has revealed that local tissue inflammation is closely involved in the rupture of atherosclerotic plaque.1 Stabilization of atherosclerotic plaque by strictly managing the... more

Inflammation Revisited: Atherosclerosis in the Post-CANTOS Era

Oct 04, 2017

Overview : The notion that atherosclerosis carries features of an inflammatory disease has existed for quite some time. As early as 1856, Rudolf Virchow in his Textbook on Pathology mentioned the term “coronaritis”. Almost 150 years later, following the elucidation of major... more

Long term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial.

Aug 11, 2014

Overview : Background and knowledge gap β-blockers reduce mortality when administered after an AMI, and are a class IA indication in this context. Experimental models have shown that intravenous administration of metoprolol before (but not after) reperfusion of STEMI reduces infarct size1,2.... more